AUA Internal Calendar | Academic Calendar | Admissions Calendar| Open Education Calendar | Library Calendar| Center for Student Success Calendar
AUA Public Events
- This event has passed.
Leadership in Science & Medicine: Presence & Vulnerability
February 7 @ 2:00 pm - 3:00 pm +04
About the Event:
The American University of Armenia (AUA) College of Health Sciences (CHS) is hosting Professor Gary D. Hammer, M.D., Ph.D., for an engaging presentation on Leadership in Science & Medicine.
About the Speaker:
Gary D. Hammer, M.D., Ph.D. is Professor in Departments of Internal Medicine (MEND), Cell & Dr. Gary D. Hammer is a professor in the departments of Internal Medicine (MEND), Cell & Developmental Biology, and Molecular & Integrative Physiology at the University of Michigan (UofM) School of Medicine. He currently serves as director of the Endocrine Oncology Program at the Rogel Cancer Center, where he holds the Millie Schembechler Professorship in Adrenal Cancer. He is the former director of the Center for Organogenesis: Stem Cells & Regenerative Medicine. He has brokered the recent renaissance of the current Michigan team of adrenal scientists, which is a who’s who in the study of adrenal disease. He received the UofM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research, and is a member of ASCI and AAP. He has served in numerous leadership roles at UofM and in the public and private sectors, including his recent tenure on the Board of Scientific Advisors for NCI. He is the editor of four textbooks, including Pathophysiology of Disease: An Introduction to Clinical Medicine (McGraw Hill) and the adrenal section editor for Degroot’s Endocrinology (Elsevier). He has served in numerous capacities for the world’s largest endocrine organization, the Endocrine Society, including his most recent role as president of the society (2020-2021). An advisor to the Congressional H.E.L.P. committee, he co-authored the 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act’ introduced in Congress in 2009. He has been a catalyst for the formation of two international cooperative groups, most recently the A5 (American Australian Asian Adrenal Alliance), which leverages collaboration to secure projects from Pharma and funding agencies across the spectrum of adrenal diseases. He is a co-founder of two companies — MILLENDO and SLING THERAPEUTICS — that focus on rare endocrine diseases.